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GLASS HOUSES:
THE POWER OF MONEY IN BIOETHICS RESEARCH
Jocelyn Downie
Abstract
In this paper I explore the power of money in bioethics research and ask wheth-
er, while casting stones regarding nancial conicts of interest in health research, 
bioethics researchers are in fact living in glass houses. I rst review the need 
for money in bioethics research, the sources of money, and key features of the 
money (specically, the amount of money involved and the fact that the money 
oen is embedded, encumbered, and required to be matched). Next I explore a 
range of possible objectives for the money transfer. I then examine the eects of 
this transfer and raise some questions and concerns about the role of money in 
bioethics research. I close with some suggestions for possible responses to these 
questions and concerns—suggestions concerning what bioethics researchers as 
individuals and as a community could do to more positively and progressively 
harness the power of money in bioethics research.
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Introduction
In recent years, many bioethicists have spent considerable time and ink doing 
what might (uncharitably) be characterized as “throwing stones” regarding nancial 
conicts of interest and health research. For example, bioethicists have been critical 
of drug companies sponsoring university research and universities commercializing 
their research (Downie and Herder 2007). !ey have painstakingly connected the 
dots—Olivieri, the University of Toronto, Apotex, . . . money (Downie, Baird, and 
Thompson 2002). Healy, Eli Lilly, . . . money (Healy 2002, 2003). Vioxx, 
Merck, . . . money (Topol 2004; Beller 2005). Gelsinger, the University of Pennsyl-
vania, . . . money (Gelsinger and Shamoo 2008). !ese critiques have been impor-
tant, and we should continue to critically reect on the place and power of money 
in health research and health care. However, it is also important to step back, cast 
a critical eye on the power of money in bioethics research itself, and ask whether 
bioethics researchers are living in glass houses. In this paper, the very lens that has 
been focused on science and medical research is used to look at bioethics research 
and both direct, and indirect, conicts of interest for bioethics researchers. I rst 
review the need (real or perceived) for money in bioethics research, the sources of 
money, and some features of the money that are important for the subsequent 
analysis. Next, I explore a range of possible objectives for the transfer of money into 
bioethics research. I then examine the eects of this transfer and discuss some 
questions and concerns that I have about the role of money in bioethics research. 
In an eort to end on a constructive note, I close with some suggestions for possible 
responses to the questions and concerns—suggestions concerning what bioethics 
researchers, as individuals and as a community, could do to harness the power of 
money in bioethics research in more positive and progressive ways.
I use Canadian examples throughout this paper as it is the context within 
which I live and work and so it is what I know best. !at said, the issues that I 
raise are relevant for many other countries, and I hope that bioethics researchers 
in these other countries will reect on the Canadian experience as it relates to 
their own. Glass houses are not a uniquely Canadian phenomenon (Eckenwiler 
and Cohn 2007).
The need for money in bioethics research
Individual bioethics researchers, quite obviously, need income whether it 
be to supplement university or hospital salaries or as their sole means of support 
as independent contractors. !ey may also need money to support their re-
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search, for example, to pay for research assistance, computer equipment and 
support, and travel to conferences. !ey may also need money to subsidize their 
other non-research bioethics activities—in particular, teaching and service.
Institutions in which bioethics research is conducted also need money to 
support their research missions. For bioethics research, this support most com-
monly takes the form of research infrastructure including o"ce space, equipment, 
supplies, and support services for research sta. Institutions also need money to 
support their non-research activities (again teaching and service) and oen use 
money derived from research activities to underwrite these non-research activities. 
It is also important to note here that bioethics research oen takes place in institute 
or center structures. !is creates a more direct institutional need for money be-
cause institutes and centers are oen required to be more nancially independent 
and self-sustaining than traditional university departments or faculties. !erefore, 
bioethics institutes and centers oen must raise not only research funds but also 
operating funds (including their own faculty salaries).
The sources of funding for bioethics research
Where attention has been paid to money and conicts of interest in bioeth-
ics, it has typically focused on funding owing from industry for contract re-
search, consulting services, and advisory board membership (Sharp et al. 2008; 
Elliott 2005; Turner 2004). Various industries have been examined, including 
the pharmaceutical, biotechnology, and insurance industries, as well as the ven-
ture capital sector. However, there are numerous other sources of money in 
bioethics research that deserve attention. We must also look hard at research 
funding agencies (e.g., the Canadian Institutes of Health Research, the Canadian 
Foundation for Innovation),1 government departments (e.g., Health Canada and 
Industry Canada), and arms-length (ow through) sui generis entities such as 
the Stem Cell Network (SCN) and Genome Canada.2
!e metaphor of the iceberg is relevant here. !e most visible part of the 
iceberg, the connections between researchers and funders that are easy to nd, are 
largely not-for-prot entities: universities, hospitals, funding councils, advisory 
committees, and health charities.3 Delve deeper and you nd government: Health 
Canada, Industry Canada, the federal Department of Justice, and provincial de-
partments of health and economic development and trade. Delve still deeper and 
you nd industry: Roche, Sciona, Esso, BioEnvelop, Merck Frosst, Schering, Glaxo-
SmithKline, Bayer, Pzer, and Sun Life Financial Canada. All of these entities have 
provided money for bioethics research or researchers in Canada.
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!e iceberg metaphor applies here to the various sources of funding and 
their relative (in)visibility on researchers’ curriculum vitae, websites, PowerPoint 
disclosure slides, survey responses, and journal articles—how much of the fund-
ing are we actually seeing or even able to see? !e metaphor applies also to the 
eects of money on bioethics research and the concerns about these eects that 
will be discussed later in this paper—are we steering straight for something that 
has the potential to sink our enterprise?
Some features of funding for bioethics research
!e features of research funding that are most relevant for the analysis 
that follows are the large amounts of money involved, as well as the fact that the 
money is oen embedded, encumbered, and required to be matched.
Large amounts of money for bioethics research
!e amounts of money awarded for bioethics research can be very large 
in both absolute and relative terms. Consider the following data from the web-
sites of various national funding organizations:
Total approved budgets for Genome Canada genomics and ethical, 
environmental, economic, legal, and social issues (GE3LS) (2001–10)—
$33,589,484 (average per grant $3,732,164) (Genome Canada a)
Total Stem Cell Network on Public Policy and Ethical, Legal, and So-
cial Issues (ELS) (2001–7)—$2,179,022 (average per grant $77,822) 4
Total Canadian Institutes of Health Research (CIHR) on ethics re-
search (1999–2009)—$6,519,738 (average per grant $123,014)5
Total Social Sciences and Humanities Research Council (SSHRC) on 
bioethics (1998–2008)—$838,745 (average per grant $22,668)6
Embedded nature of bioethics research
Not only are the amounts awarded for bioethics research frequently large, 
but the projects are also frequently embedded within large-scale science projects. 
!at is, the bioethics projects are an integral part of the applications submitted 
for the large-scale science projects and then continue to operate within the large 
infrastructure. !ere is a nancial (inter)dependence. For example, the Stem 
Cell Network submitted one large application for funding through the Network 
of Centres of Excellence Canada program. !e embedded nature of the bioethics 
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research is reected well in the description of the “Strategic Program IV” on 
the SCN website:
Past (1st cycle) research was conducted in two fundamental ways. First, SCN 
established a program of basic research aimed at creating an integrated and 
interdisciplinary analysis of those ethical, legal and social issues (ELSI) in 
both Canadian and international contexts. Second, ELSI researchers were 
integrated into many of the projects funded under Programs 1, 2 & 3, where 
ELSI support and guidance was warranted.
 Current (2nd cycle) research is focused on projects that are of interest to 
policymakers and to an ELSI core facility. !e ELSI core facility liaises with 
Strategic Programs 1 & 2 projects to identify emerging ELSI issues, to map out 
an expected timeline to the clinic and potential legal/ethical barriers that will 
arise. Guided by the SCN’s Clinical Trials committee, the facility prioritizes 
where the Network can have the most impact in easing the ethics/regulatory/
policy pathways and undertakes or co-ordinates work to address the hurdles.
. . . 
 !e clinical focus of Programs I & II is supported and enabled by the 
research undertaken as part of Programs III & IV. Strategic Program III ad-
dresses the need for novel tools, reagents and devices, and is comprised both 
of independent projects as well as components integrated into projects from 
across the research portfolio. Strategic Program IV [public policy and ethical, 
legal, and social issues] combines a research program that examines the wider 
public policy issues arising from stem cell technology with a core facility that 
will provide direct advice and support to clinical projects. (Stem Cell Network; 
emphasis added)
Similarly, Genome Canada was set up to embed what it called genomics and 
ethical, environmental, economic, legal, and social issues (GE3LS) within the large 
science project infrastructure. Genome Canada “was given a mandate by the 
Government of Canada to develop and implement a national strategy for sup-
porting large-scale genomics and proteomics research projects, for the benet of 
all Canadians.” (Genome Canada b) In turn, regional Genome centres were set 
up across the country to engage in large-scale genomics research. Each Genome 
centre had to submit an application for funding and had to include a GE3LS com-
ponent in their application. Each centre was required to set up a GE3LS program 
and each large-scale project was required to “include a plan to address those 
GE3LS aspects directly raised by the research” (Genome Canada b).
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!e phenomenon of embedding bioethics research within science projects 
is also manifest in a large number of CIHR grants and initiatives funded by 
other entities.7
The encumbered nature of bioethics research funding
!e funds for bioethics research are also frequently encumbered. !at is, they 
come with strings attached—goals in addition to the performance of the research. 
For example, many funders of bioethics research have an explicit commercialization 
mandate or mission. !e Canadian Institutes of Health Research Act states that:
4. !e objective of the CIHR is to excel, according to internationally accepted 
standards of scientic excellence, in the creation of new knowledge and its 
translation into improved health for Canadians, more eective health services 
and products and a strengthened Canadian health care system, by
. . . 
(i) encouraging innovation, facilitating the commercialization of health 
research in Canada and promoting economic development through 
health research in Canada.8
Genome Canada’s commercialization mandate can be inferred from the 
evaluation plan for March 2009, which is based on the objectives outlined in 
the funding agreement with Industry Canada:
!e evaluation will measure overall performance in achieving the objectives 
identied in the Funding Agreement. !e evaluation will include a review 
of the following:
. . . 
(d) commercialization and corporate development. (Genome Canada b).
!e Stem Cell Network’s mission is “To be a catalyst for enabling transla-
tion of stem cell research into clinical applications, commercial products and 
public policy” (Stem Cell Network).
Bioethics research funds coming from these sources thus may come with 
a heavy commercialization encumbrance.
Matching requirements for bioethics research funding
Finally, granting entities sometimes require that the funds they provide be 
matched by funds from other sources. For example, for Genome Canada, “[T]he 
agreement with the Government of Canada stipulates that Genome Canada will 
raise the other 50 per cent of funding from other sources” (Genome Canada b). 
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Similarly, the CIHR Innovation and Industry programs are designed to help the 
academic community “interact with Canadian companies with an interest in 
health research and development. !e programs promote a wide variety of peer-
reviewed research and training projects jointly funded by Canadian companies 
and CIHR” (Canadian Institutes of Health Research; emphasis added). CIHR 
funds are matched 1:1 or 1:2 by industry within these programs.
Objectives of funding bioethics research
!ere are, of course, many admirable objectives for the funding of bioeth-
ics research: to advance knowledge and knowledge transfer, to increase ethical 
research and practice, and to increase ethical policy development. However, 
there are also other, less savory, possible objectives, including to:
Co-opt—“to neutralize or win over through assimilation”
Restrict—“to keep or conne within limits”
Use—“to seek or achieve an end by means of”
Shape—“to give a particular form to, . . . to cause to conform to a par-
ticular form or pattern, . . . to adapt to a particular use or pur-
pose, . . . to direct the course of”
Harness—“to bring under control and direct the force of.”9
With these sources, features, and objectives in the background, I turn now to 
the possible eects of money on bioethics research.
Possible effects of money on bioethics research
Money has several potential positive eects on bioethics research. It creates 
jobs for bioethics researchers. It provides nancial rewards for bioethics research-
ers. It provides funds for research but also, indirectly, for education, policy devel-
opment, and service in bioethics. It might also lead to bioethics research being of 
greater relevance; if people are willing to pay for it, the argument goes, we might 
reasonably assume that it has greater relevance to them. !is could apply to direct 
consumers such as industry (e.g., commissioning papers on topics that directly 
aect it), as well as indirect consumers such as the public through national fund-
ing agencies (e.g., setting strategic themes for targeted research and directing 
money to those themes that are thought to be in the public interest).
Such eects are certainly attractive. However, there are also a number of 
signicant negative eects that are possible. Money can have a negative eect 
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on what we do, what we don’t do, what we say (and how we are heard), and what 
we don’t say. Consider each in turn.10
What we do
Shifting to empirical research
When embedded in large scale science projects, the budgets for bioethics 
research projects are oen required to be very large. To be in the game, budgets 
run in the hundreds of thousands rather than tens of thousands of dollars. Yet 
non-empirical bioethics research tends not to cost that much. Empirical research 
drives the costs up and so puts bioethics research in the budgetary ballpark of 
the embedded projects. If the research questions demand empirical research, 
then the inclusion of empirical work is justiable. However, if the inclusion of 
empirical research is driven by a need to ramp up the budget, then serious ques-
tions should be asked.
Adopting the lab model
Another eect of embedding is the adoption of the lab model for personnel 
and a consequential increase in the student and research associate involvement 
(oen as authors, whether acknowledged as such or not) and a consequent shi 
in the kind of research that can be done. !e lab model is frequently adopted 
by embedded bioethics research for two reasons: rst, it ramps up the budget; 
second, a lab model is the cultural norm in much of science, so the expenditures 
are recognized as legitimate by the science collaborators and in the peer review 
of the budget justications. However, when you adopt the lab model, you see 
the involvement of a large number of junior researchers, fewer in the middle 
ranks, and very few senior researchers. !e level of research capacity is dierent 
at the dierent levels of seniority, and yet there are not the same levels of work/
divisions of labor possible in non-empirical bioethics research as there are in 
science research. As a gross oversimplication, rst take a neuropsychology 
research project on the acquisition of second languages. It takes the senior pro-
fessor to design the study, but it also takes a lab full of students to run the 
participants through the functional Magnetic Resonance Imaging (fMRI) tests. 
Now take a philosophy research project on a relational approach to the concept 
of personal identity. !e conceptual analysis cannot be broken down into com-
ponent parts that a group of undergraduate or graduate philosophy students 
can do following the design of the study by the senior philosophy professor. 
Embracing the lab model (in part, encouraged or necessitated by the budget 
issue discussed above) changes the kind of bioethics research done; for example, 
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the research tends to be more empirical and less conceptual/theoretical. Of 
course there is value in empirical bioethics research. Consider, for example, the 
value of the meta-analysis that was done to demonstrate a positive results bias 
in industry-sponsored medical research (Bekelman, Yan, and Gross 2003; Lex-
chin et al. 2003). However, empirical work should not be allowed to crowd out 
conceptual and theoretical work.
Moving the ethics questions downstream
Still another eect of embedding is a shi with respect to the starting point 
for the analysis. Once embedded, researchers spend more time asking “How do 
we do X ethically?” and less time asking “Is it ethical to do X?” When the science 
partner is already trying to do X, it will not be seen as legitimate by the team for 
the bioethics partner to question doing X. And yet, the prior question must at least 
be permitted to be asked even if not asked. A related eect of embedding is that 
more time is spent on partner service—research into questions that the science 
partners would like to have answered in service to their research. For example, in 
embedded projects one might expect to see more research into developing consent 
forms for stem cell transfer research than into intergenerational justice issues ow-
ing from personalized stem cell medicine. An example of this phenomenon can 
be found in the evolution of the Stem Cell Network. Indeed, in the latest round of 
funding, this tendency appears to have been taken to an extreme. !ere is now a 
“core facility that will provide direct advice and support to clinical projects”:
Current (2nd cycle) research is focused on research projects that are of inter-
est for policymakers and to an ELSI core facility. !e ELSI core facility liaises 
with Strategic Programs 1 & 2 projects to identify emerging ELSI issues, to 
map out an expected timeline to the clinic and potential legal/ethical barri-
ers that will arise. Guided by the SCN’s Clinical Trials committee, the facility 
prioritizes where the Network can have the most impact in easing the ethics/
regulatory/policy pathways and undertakes or co-ordinates work to address the 
hurdles. (Stem Cell Network; emphasis added)
Shifting the publication venues
!e sources and features of money in bioethics research have also led to 
bioethics researchers increasingly writing in styles and publishing in venues that 
arguably do not lend themselves to the advancement of bioethics scholarship.11 
Specically, when embedded or looking to embed with the large science projects, 
quality is measured in numbers of peer-reviewed publications, impact factors of 
the journals where published, and other measures of quality established for sci-
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ence research. !is leads to an emphasis on peer-reviewed articles over invited 
articles and book chapters and to shorter articles written for science audiences in 
particular journals.12 With this shi, the complexity of analysis can be lost, as can 
be high-level debate in the literature among bioethics research peers.
Embracing the role of entrepreneur
!e need for and availability of money may also lead bioethics researchers 
to become entrepreneurs (e.g., forming spin-o companies). One example is 
GenomePolicy Inc. !is private company, apparently13 spun out of the University 
of Toronto bioethics research context, oered a course called !e Genome Policy 
Program, which was sponsored by GSK, Merck, Pzer, and the Ontario Genomics 
Institute, but nonetheless cost participants $5,350 for three days (not including 
accommodation). !e course was delivered at the University of Toronto School 
of Management Executive Education facility, and the program directors were 
faculty members at the Joint Centre for Bioethics and the School of Management 
at the University of Toronto, but checks were to be payable to GenomePolicy Inc. 
!e website for the Genome Policy Program is registered to the Director of Opera-
tions and Scientic Strategy at the McLaughlin-Rotman Centre for Global Health, 
Program on Life Sciences, Ethics and Policy at the University of Toronto.
Narrowing the bioethics research agenda
!e sources and features of money in bioethics research outlined above have 
also led to a large relative and large absolute amount of work being done on a narrow 
range of issues (that is, relating to genetics, genomics, and stem cell research). !e 
narrow range is illuminated by reference to the fact that 24 percent of all CIHR ELH 
ethics funding relates to genetics/genomics and that GE3LS funding is ve times 
greater than all CIHR ELH ethics funding. !e high volume is illuminated by refer-
ence to the totals spent on GE3LS ($33,589,482) and SCN ELS ($2,179,022).
What we don’t do (enough)
As a result of the funding sources and features outlined earlier, bioethics 
researchers may not do enough of the following:
Research on vulnerable populations issues—As has been demonstrated 
above, a great deal of bioethics research is done on genetics and genomics issues 
but far less is done on issues aecting vulnerable populations, such as access to 
abortion for rural women or aboriginal health law and policy. Where is the work 
by Canadian bioethics researchers on aboriginal people in Canada, unsafe 
drinking water in Africa, and human rights in China? (Turner 2007).
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Conceptual or theoretical research—A great deal of bioethics research is 
done on such pragmatic and programmatic issues as consent to treatment or 
research, but much less is done on the conceptual analysis of such issues as 
identity, trust, and justice in the health context or such theoretical projects as 
developing relational theory.
Critical research—A great deal of bioethics research is compatible with (if 
not outright supportive of) commercialization. Less is done that is critical work, 
for example, on the ethics of the commercialization mandate of national funding 
agencies and the ethics of promoting genomics in developing countries. Another 
example of a gap in critical research is in the area of research on bioethics re-
search. It would be valuable to have a textual analysis study on the impact that 
the various sources, amounts, and purposes of bioethics research funding have 
on the results of the research but to do this properly would require researchers 
with appropriate methodological expertise (at least some from outside bioeth-
ics), transparency from the bioethics research community, positive peer reviews 
from the bioethics research community (as this empirical research would re-
quire research funds), and a safe environment for such research (the protection 
of academic freedom for the researchers and a bioethics research community 
that does not penalize researchers for conducting such research).
Investigator-driven research—Topics for bioethics research are increasingly 
set by funding-agency strategic themes or by science collaborators and not by 
the bioethics researchers themselves. Although not all investigator-driven re-
search is necessarily in the public interest, at least some of it is, and so there is 
an argument to be made to protect and promote investigator-driven bioethics 
research (particularly where the investigators are responsive to the needs and 
interests of the public).
Books and lengthy academic papers—!is is the ip side of the issue of 
publishing in science journals mentioned earlier. When bioethics researchers 
write many short papers for science journals with high impact factors, then we 
don’t write as many books and lengthy academic papers published in our own 
disciplinary journals. Yet length is essential for much of the complex ethical 
analysis that is actually required to advance understanding. !e shi to science 
journals changes the nature and quality of the discussion. When we reduce the 
number of books and lengthy academic papers, we ultimately diminish the 
intellectual value and legitimacy of our eld. !is is, of course, not to say that 
bioethics researchers should not publish in science journals. !ere is an essential 
role for the translation and dissemination of research results in formats and fora 
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that reach across disciplines and sectors. However, knowledge translation should 
not be confused with knowledge production, and knowledge production in bio-
ethics oen requires the length aorded by books and very high word counts.
What we say and don’t say
An interesting illustration of one concern about what we as bioethics re-
searchers say comes from a comparison of the media content generated by bioeth-
ics researchers on genetics, genomics, and stem cell research in contrast to the 
media content generated by bioethics researchers on the increasing threats to the 
public health system in Canada. A number of bioethics researchers were very much 
out in public when governments sought to restrict the activities of scientists (e.g., 
the regulation of research involving human embryos),14 but where were they when 
the Chaoulli decision15 came down? !e concern is whether, by shaping what re-
searchers specialize in, the sources and features of money in bioethics research 
aect what topics bioethics researchers are qualied to speak out about.
Another concern about what we as bioethics researchers say is whether there 
is a pro-funder bias or apprehension of bias in our communication. Are we, or are 
we seen to be, pro-funder (or pro the funders’ interests or objectives)? In response 
to skeptics on this, I would oer a question and a comment: (1) why would funders 
provide funds the way they do if doing so didn’t work (i.e., advance their interests 
or objectives)? and (2) physicians thought that their prescribing patterns weren’t 
aected by detailers and other industry “interventions,” but they clearly were. As 
noted earlier, positive results biases have been well-demonstrated now in compari-
sons of research funded by industry with research not funded by industry (Bekel-
man, Yan, and Gross 2003; Lexchin et al. 2003). We should not wear the same 
blinders in the bioethics research community.
!e sources and features of money in bioethics research may also aect 
what we don’t say. Because of the need for money and the fact that much of the 
money that is available is encumbered or requires embedding or matching 
funds, bioethics researchers may be unwilling to say the following:
Matters covered in con"dentiality clauses—!e issue of condentiality 
clauses in science research has received a great deal of attention (!ompson, 
Baird, and Downie 2001).16 !ere has been much discussion, for example, about 
the balancing of the interests of companies in protecting proprietary information 
prior to obtaining a patent against the interests of research participants in receiv-
ing information about harms that are discovered in the course of a research study. 
However, little attention has been paid to condentiality clauses in bioethics re-
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search. And yet, some of the worst clauses I have seen have been in contracts given 
to bioethics researchers to sign. For example, some bioethics researchers in Can-
ada agreed, in the context of research embedded in a large science project, to be 
bound by an agreement in which the parties were required to not disclose any 
condential information without the prior written consent of the other party; 
“condential information” was any information designated as condential by one 
party and provided to the other party. !e agreement also included up to a six-
month delay of the publication of research results by the bioethics researchers.17
Statements critical of employers—In part because of the structures within 
which bioethics researchers work (which in turn are partially a result of funding 
issues as noted earlier in the paper), bioethics researchers do not always have 
academic freedom; sometimes they are employed in faculties of medicine or in 
hospitals without the academic freedom protection of tenure. Without such 
protection, they may feel constrained from speaking out about the results of 
their research. Consider, for example, a bioethics researcher who comes to the 
conclusion that donation aer cardiac death (DCD)18 is neither ethical nor legal. 
If she works in a health center that has implemented DCD, will she be willing 
and able to speak out against it?
Statements critical of current (or potential future) funders and current (or 
potential future) science collaborators—Will bioethics researchers self-censor in 
an eort to build or maintain relationships with funders and collaborators? Evi-
dence of this is, for obvious reasons, di"cult to nd—is silence due to agreement 
or to self-censorship?
!is discussion of the possible eects of money on bioethics research leads 
to a set of concerns about money and bioethics research.
Questions and concerns about money and bioethics
Based on the preceding exploration of the features, sources, and eects of 
money on bioethics research, I am le with a set of questions.
First, are we witnessing an unjust expenditure of resources within bioethics 
research? For example, what might the $33.5 million spent on GE3LS by Genome 
Canada have accomplished if spent instead on ethics research related to health 
care and the disempowered in Canada (e.g., the failure to meet the health needs 
of many disadvantaged minorities or the privatization of health care)?
Second, are we witnessing an unjust expenditure of resources more gener-
ally (beyond Canada and beyond bioethics)? The money spent by Genome 
Canada (and its matching funders) on GE3LS could provide health care for one 
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year for 11 million people from Burundi or 5.5 million Ethiopians. What could 
$33.5 million do for suicide prevention in aboriginal communities in Canada?
!ird, are we giving value for money? Can we really give good value for 
$33.5 million for GE3LS research? How many qualied researchers are there in 
bioethics in Canada? How many are doing this work? How many are experts in 
the eld? How many hours are there in a day?
!e preceding exploration also leads me to a set of concerns about the 
eects of money on bioethics research. Will our research be of less relevance for 
the vulnerable? Will we have less independence? Will we have and deserve less 
credibility? Will we have and deserve less respect? Ultimately, and most impor-
tantly, will we be less able to make a positive dierence to the lives of those who 
most need our help?
New directions
In response, the bioethics research community could take a number of steps.
First, we could be more aware of our contexts of privilege (both relative to 
residents of our own countries and to individuals in other countries) and explore 
our derivative obligations.
Second, we could rethink our needs. We can easily get caught up and think 
that we need what we really just desire.
!ird, we could expose the structures that construct/sustain needs (e.g., 
setting up centers and institutes without hard money so that there is a never-
ending requirement to generate funds).
Fourth, we could be more aware of the potentially negative eects of money 
in bioethics research, particularly:
Industry funding of bioethics researchers and institutions
Sources of funding in addition to industry
Eects in addition to co-opting
Eects of embedding
Effects of the absence of tenure or similar protections for academic 
freedom
Fih, we could explore ways to better balance the positive and negative 
eects of money in bioethics research, particularly:
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Require meaningful transparency of funding (personal and institutional)—
including disclosure of all amounts, sources, and purposes—whenever 
disseminating the results of bioethics research (in whatever the fora)19
Establish standards around conduct, working conditions, funding 
conditions, and institutional structures for bioethics researchers20
Promote and protect academic freedom for bioethics researchers21
Lobby for core funding for bioethics institutes and centers
Promote collaboration models between scientists and bioethics researchers 
that do not create nancial (inter)dependence
Lobby for greater emphasis on investigator-driven, non-partnered, non-
embedded research funding22
If we do nothing, we will lose the moral authority or even basic legitimacy 
with respect to critiquing the power of money in science and medical research. 
If we do something, we could lead by example, and we could regain the capacity 
to make a positive dierence in the world. We are good at throwing stones but, 
as the saying goes, people who live in glass houses. . . . It is beyond time to move 
out of our glass houses.
Notes
I would like to thank Brad Abernethy, Françoise Baylis, and other members of 
the NovelTechEthics group at Dalhousie University for helpful comments on 
earlier dras of this paper. !anks also to Matthew Kutcher and Jennifer Adams 
for their very helpful research assistance.
1. !e Canadian Institutes of Health Research (CIHR) is the Government of 
Canada’s health research funding agency. !e CIHR is comprised of thirteen “vir-
tual” institutes (e.g., !e Institute of Cancer Research) that coordinate funding 
according to the CIHR mandate “to excel, according to internationally accepted 
standards of scientic excellence, in the creation of new knowledge and its transla-
tion into improved health for Canadians, more eective health services and prod-
ucts and a strengthened Canadian health care system,” http://www.cihr-irsc.gc 
.ca/ (accessed January 26, 2009). !e Canadian Foundation for Innovation (CFI) 
“is an independent corporation created by the Government of Canada in 1997 to 
fund research infrastructure. !e CFI’s mandate is to strengthen the capacity of 
Canadian universities, colleges, research hospitals, and non-prot research institu-
tions to carry out world-class research and technology development that benets 
Canadians,” http://innovation.ca (accessed January 26, 2009).
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2. !e Stem Cell Network is a non-prot corporation formed in 2001. !e SCN 
is part of Canada’s Networks of Centres of Excellence, and it provides targeted re-
search funding aimed at “enabling the translation of stem cell research into clinical 
applications, commercial products and public policy,” http://www.stemcellnetwork 
.ca/ (accessed January 26, 2009). Genome Canada is a non-prot organization man-
dated by the Canadian Government to “develop and implement a national strategy 
for supporting large-scale genomics and proteomics research projects for the benet 
of all Canadians,” http://www.genomecanada.ca/ (accessed January 26, 2009).
3. For example, CIHR, Genome Canada, the Stem Cell Network, the Cana-
dian Biotechnology Advisory Committee, the Huntington Society of Canada, and 
the Kidney Foundation of Canada.
4. !is information was available on the Stem Cell Network website (www 
.stemcellnetwork.ca) in September 2008; however, as of January 26, 2009, it appears 
to have been removed from the site.
5. It is di"cult to determine precisely the amount of money spent by CIHR 
on what can be characterized fairly as ethics research. If one searches the funded 
research database using the single term “ethics,” the results are seriously 
 over-inclusive—ethics can be a very peripheral part of a large science project and 
yet be included in the search results. In an eort to compare apples with apples 
(with respect to the comparators cited above), I therefore restricted my search 
to those grants handled by the Ethics, Law, and Humanities (ELH) peer review 
committee.
6. Based on all grants in the SSHRC-funded research database having “bio-
ethics” as a keyword from 1998 to 2008. Again seeking consistency with other 
comparators, graduate student awards were not included.
7. For example, when one searches “ethics” on the CIHR-funded research 
database and does not limit the projects included to those handled by the ELH 
peer review committee, the funding jumps from $6,519,738 to $62,492,344.
8. Bill C-13, Canadian Institutes of Health Research Act, 2nd sess., 36th Par-
liament, 1999–2000 (assented to 13 April, 2000), 48–49 Elizabeth II, c.6.
9. Canadian Dictionary of the English Language (Toronto: International 
!omson Publishing, 1998).
10. I should note here two di"culties associated with gathering evidence of 
the eects of money on bioethics research. First, a great deal of relevant informa-
tion is not available. For example, the amounts and purposes of the money involved 
are not transparent. Many researchers do not include such information in their 
CVs available online. Second, it can be (or have the appearance of being) dangerous 
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to engage in such research. I was told that aer I had given a talk that raised ques-
tions about competing interests and obligations for health law and policy research-
ers, the following comment was made in relation to my talk (among a group of 
researchers in the eld who were together): “Her career is over.” Imagine the chill-
ing eect of such a comment on me and on any other researcher who heard about 
it—these were people who could have a direct impact on my future access to re-
search funding and career opportunities.
11. I compared the venues and page lengths of publications of two illustrative 
Canadian researchers—one known for doing a lot of embedded/encumbered re-
search and one known for not doing a lot of it. Both are considered highly accom-
plished researchers. !e one who does a lot of embedded/encumbered research 
published 49 percent of the time in science or medicine venues and 51 percent of 
the time in ethics, law, and social issues (ELSI—a common category for bioethics 
research) venues with an average of thirteen pages per publication. !e one who 
does not do a lot of embedded/encumbered research published 9 percent of the 
time in science or medicine venues and 91 percent of the time in ELSI venues with 
an average of twenty-six pages per publication. Of course, a more comprehensive 
review of the literature and practice would be required to press this point, and it 
would require the cooperation of a number of bioethics researchers (so as to be 
able to determine levels of participation in embedded/encumbered research).
12. For an illustrative example, see the table re: publications, found in the CIHR 
Common CV module at www.commoncv.net (accessed January 26, 2009). A two-
page article counts as much as a y-page article. For some of the problems with 
transferring metrics from science to non-science disciplines, see, e. g., the reaction 
to the European Reference Index for the Humanities, http://www.corporeality.net/
museion/2008/07/17/humanities-journals-under-threat-from-the-european- 
research-bureaucracy-erih (accessed January 26, 2009). For a discussion of the prob-
lems with impact factors see Richard Smith, “Commentary: !e power of the unre-
lenting impact factor—Is it a force for good or harm?” International Journal of Epi-
demiology 35 (5) (2006): 1129–30.
13. In a search conducted by a professional business librarian, only the fol-
lowing information about this company’s executives could be found: “Jerey L. 
Sturchio, Vice President, External Aairs, Human Health [Merck & Co. Inc.] 
Jonathan Kay, Editorials Editor of the National Post Newspaper Adrian Ivinson, 
Director, Harvard Center for Neurodegeneration and Repair, Harvard Medical 
School.” Netvention Company Proles. Generate, Inc. (2007). Netvention Com-
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pany Proles: !e Genome Policy Program. Retrieved September 29, 2008, from 
Lexis-Nexis Academic database.
Another source listed Jerey Sturchio, Adrian Ivinson, Peter Singer, Alan 
Bernstein, and Roderick McInnes as the “Genome Policy Program Executives,” 
http://www.baltimore.bizjournals.com (accessed January 26, 2009).
14. Assisted Human Reproduction Act, 2004, c.2.
15. Quebec Attorney General v. Chaoulli [2005] 1 S.C.R. 791, 2005 SCC 35.
16. For a detailed discussion of the Canadian case that received the most 
attention and precipitated signicant changes in practice, see Jon !ompson, Pa-
tricia Baird, and Jocelyn Downie, “!e Olivieri Report: !e complete text of the 
report of the independent inquiry commissioned by the Canadian Association of 
University Teachers” (Toronto: James Lorimer and Company Ltd., 2001).
17. Dra agreement on le with the author.
18. DCD involves the removal of organs for the purposes of transplantation 
following determination of death according to cardiac criteria rather than neuro-
logical criteria (cardiac vs. brain death).
19. Journal editors could take rst steps toward this goal by requiring disclo-
sure of all funds (whether for the particular paper being published by them or not) 
by bioethics researchers and making the information accessible to the public 
through the journal websites or a central database, housed publicly on the Web, 
which researchers were required to keep complete and current as a condition of 
publishing in participating journals.
20. See, e.g., the work of the Canadian Bioethics Working Group on Working 
Conditions for Bioethics in Canada, http://www.bioethics.ca/publications-ang.html 
(accessed January 26, 2009).
21. See, e.g., policy statements on academic freedom, http://www.caut.ca 
(accessed January 26, 2009).
22. E.g., an increase in open operating grants from CIHR (www.cihr-irsc.gc.ca) 
and SSHRC (www.sshrc.ca) and an expansion rather than a reduction in Canada 
Research Chairs (www.chairs.gc.ca).
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